Powered By
Below is a link to research conducted by Washington University School of Medicine in St. Louis and published Feb. 13, 2025 in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, on behalf of the Alzheimer’s Association.
The purpose of the study was to provide actionable information, to help Alzheimer’s patients and caregivers weigh the benefits against the costs and risks of treatment with lecanemab (Leqembi) and/or donanemab (Kisunla): ie, with treatment, how much longer… read more
Answer Summary
Members discussed a new study on lecanemab and donanemab, drugs that can extend independent living by 8 to 10 months for people with very... Read more
Adding a note here regarding a mention by @A myALZteam Member (made on a different post, but in regard to this research.) He wrote:
"A few days ago you Posted in Q&A about Lecanemab and Donanemab. The results are impressive, nearly a year extra of independent living."
This is great info, thanks @A myALZteam Member
Yes, I keep all my appointments in my phone also. The day clock is a wonderful invention, and for a while it helped my husband keep track of the days of the week and the time of day.
@A myALZteam Member: I suspect that most of us keep our appointments in our phone calendars! I certainly do, because I need to coordinate appointments for 3 people (my husband, my son, and myself), and I even color-code them, to make it easier.
But do you have a Day Clock? It's ingenious, and both my husband and my son have found this to be a very helpful thing to have.
This is the trial that I am in. My wife and I feel that it is working. I receive Lecanemab by infusion every 2 weeks. Every 2nd infusion includes a 2nd test drug or a placebo. I have been in over one year now and have been holding pretty steady in our opinion. I actually received a treatment this morning. Praying for a cure!
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
